Predictors of Stability/Improvement of Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis After One Year of Treatment With Nintedanib

Mondoni, Michele; Varone, Francesco; Alfano, Fausta; Muscato, Giuseppe; Conti, Caterina; Saderi, Laura; Iovene, Bruno; Marco, Fabiano Di; Vancheri, Carlo; Richeldi, Luca; Centanni, Stefano; Sotgiu, Giovanni

doi:10.1016/j.arbres.2023.02.010

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To find a cure for this debilitating and fatal disease, it is imperative to deepen our understanding of the pathogenetic mechanisms underlying IPF, including altered cell-cell crosstalk and secretion of pathogenic molecules in the fibrotic milieu. Ongoing research continues to explore novel therapeutic options, personalized strategies and therapeutic combinations as well as possible biomarkers of diagnosis and/or predictors of treatment efficacy [ 11 ]. In this review, we provide a comprehensive summary of the current pharmacological treatments of IPF, clinical trials and future directions.…”

Section: Introductionmentioning

confidence: 99%

Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives

Vancheri,

Sciacca,

Muscato

et al. 2024

Multidisciplinary Respiratory Medicine

Self Cite

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) represents a fibrotic interstitial lung disease characterized by uncertain etiology and poor prognosis. Over the years, the path to effective treatments has been marked by a series of advances and setbacks. The introduction of approved antifibrotic drugs, pirfenidone and nintedanib, marked a pivotal moment in the management of IPF. However, despite these advances, these drugs are not curative, although they can slow the natural progression of the disease. The history of drug therapy for IPF goes together with the increased understanding of the pathogenic mechanisms underlying the disease. Based on that, current research efforts continue to explore new therapies, possible personalized treatment strategies, drug combinations, and potential biomarkers for diagnosis and prognosis. In this review, we outline the route that led to the discover of the first effective therapies, ongoing clinical trials, and future directions in the search for more effective treatments.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives

Vancheri,

Sciacca,

Muscato

et al. 2024

Multidisciplinary Respiratory Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…No scientific data are available on the slow course of disease in the elderly. Furthermore, no demographic, clinical, and functional variables may predict the stabilization/progression of disease, even in patients exposed to antifibrotic therapy [5].…”

mentioning

confidence: 99%

Do We Really Need to Treat Over-80-Year-Old Patients Affected by IPF? A Response

et al. 2023

Self Cite

View full text Add to dashboard Cite

Predictors of Stability/Improvement of Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis After One Year of Treatment With Nintedanib

Cited by 2 publications

References 9 publications

Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives

Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives

Do We Really Need to Treat Over-80-Year-Old Patients Affected by IPF? A Response

Contact Info

Product

Resources

About